Lauren M Janczewski, Michael R Visenio, Rachel Hae-Soo Joung, Anthony D Yang, David D O’Dell, Elizabeth C Danielson, Mitchell C Posner, Ted A Skolarus, David J Bentrem, Karl Y Bilimoria, Ryan P Merkow
{"title":"癌症胰腺切除术后中期死亡率评估","authors":"Lauren M Janczewski, Michael R Visenio, Rachel Hae-Soo Joung, Anthony D Yang, David D O’Dell, Elizabeth C Danielson, Mitchell C Posner, Ted A Skolarus, David J Bentrem, Karl Y Bilimoria, Ryan P Merkow","doi":"10.1093/jnci/djae215","DOIUrl":null,"url":null,"abstract":"Background Pancreatic cancer remains highly lethal and resection represents the only chance for cure. Although patients are counseled regarding short-term (0-3 months) mortality, little is known about mortality 3-6 months (intermediate-term) following surgery. We assessed predictors of intermediate-term mortality, evaluated hospital-level variation, and developed a nomogram to predict intermediate-term mortality risk. Methods Patients undergoing pancreatic cancer resection were identified from the National Cancer Database (2010-2020). Multivariable logistic regression identified predictors of intermediate-term mortality and assessed differences between short-term and intermediate-term mortality. Multinomial regression grouped by intermediate-term mortality quartiles evaluated hospital-level variation. A neural network model was constructed to predict intermediate-term mortality risk. All statistical tests were 2-sided. Results Of 45,297 patients, 3,974 (8.9%) died within 6-months of surgery of which 2,216 (5.1%) were intermediate-term. Intermediate-term mortality was associated with increasing T-category, positive nodes, lack of systemic therapy, and positive margins (all p < .05) compared with survival beyond 6-months. Compared with short-term, intermediate-term mortality was associated with treatment at high-volume hospitals, positive nodes, neoadjuvant systemic therapy, adjuvant radiotherapy, and positive margins (all p < .05). Median intermediate-term mortality rate per hospital was 4.5% (IQR 2.6-6.5). Highest quartile hospitals had decreased odds of treatment with neoadjuvant systemic therapy, neoadjuvant radiotherapy, and adjuvant radiotherapy (all p < .05). The neural network nomogram was highly accurate (Accuracy: 0.9499; AUC-ROC of 0.7531) in predicting individualized intermediate-term mortality risk. Conclusion Nearly 10% of patients undergoing pancreatectomy for cancer died within 6-months of which half occurred in the intermediate-term. These data have real-world implications to improve shared decision-making when discussing curative-intent pancreatectomy.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"99 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of Intermediate-Term Mortality Following Pancreatectomy for Cancer\",\"authors\":\"Lauren M Janczewski, Michael R Visenio, Rachel Hae-Soo Joung, Anthony D Yang, David D O’Dell, Elizabeth C Danielson, Mitchell C Posner, Ted A Skolarus, David J Bentrem, Karl Y Bilimoria, Ryan P Merkow\",\"doi\":\"10.1093/jnci/djae215\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Pancreatic cancer remains highly lethal and resection represents the only chance for cure. Although patients are counseled regarding short-term (0-3 months) mortality, little is known about mortality 3-6 months (intermediate-term) following surgery. We assessed predictors of intermediate-term mortality, evaluated hospital-level variation, and developed a nomogram to predict intermediate-term mortality risk. Methods Patients undergoing pancreatic cancer resection were identified from the National Cancer Database (2010-2020). Multivariable logistic regression identified predictors of intermediate-term mortality and assessed differences between short-term and intermediate-term mortality. Multinomial regression grouped by intermediate-term mortality quartiles evaluated hospital-level variation. A neural network model was constructed to predict intermediate-term mortality risk. All statistical tests were 2-sided. Results Of 45,297 patients, 3,974 (8.9%) died within 6-months of surgery of which 2,216 (5.1%) were intermediate-term. Intermediate-term mortality was associated with increasing T-category, positive nodes, lack of systemic therapy, and positive margins (all p < .05) compared with survival beyond 6-months. Compared with short-term, intermediate-term mortality was associated with treatment at high-volume hospitals, positive nodes, neoadjuvant systemic therapy, adjuvant radiotherapy, and positive margins (all p < .05). Median intermediate-term mortality rate per hospital was 4.5% (IQR 2.6-6.5). Highest quartile hospitals had decreased odds of treatment with neoadjuvant systemic therapy, neoadjuvant radiotherapy, and adjuvant radiotherapy (all p < .05). The neural network nomogram was highly accurate (Accuracy: 0.9499; AUC-ROC of 0.7531) in predicting individualized intermediate-term mortality risk. Conclusion Nearly 10% of patients undergoing pancreatectomy for cancer died within 6-months of which half occurred in the intermediate-term. These data have real-world implications to improve shared decision-making when discussing curative-intent pancreatectomy.\",\"PeriodicalId\":501635,\"journal\":{\"name\":\"Journal of the National Cancer Institute\",\"volume\":\"99 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Cancer Institute\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jnci/djae215\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jnci/djae215","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景 胰腺癌的致死率仍然很高,切除是治愈的唯一机会。虽然患者会被告知短期(0-3 个月)死亡率,但对术后 3-6 个月(中期)的死亡率却知之甚少。我们评估了中期死亡率的预测因素,评估了医院层面的差异,并开发了一个预测中期死亡风险的提名图。方法 从国家癌症数据库(2010-2020 年)中识别出接受胰腺癌切除术的患者。多变量逻辑回归确定了中期死亡率的预测因素,并评估了短期死亡率和中期死亡率之间的差异。按中期死亡率四分位数分组的多项式回归评估了医院层面的差异。建立了一个神经网络模型来预测中期死亡风险。所有统计检验均为双侧检验。结果 在45297名患者中,有3974人(8.9%)在术后6个月内死亡,其中2216人(5.1%)为中期死亡。与 6 个月后的存活率相比,中期死亡率与 T 类增加、结节阳性、缺乏系统治疗和边缘阳性有关(所有 p &p;lt;0.05)。与短期死亡率相比,中期死亡率与在大医院治疗、结节阳性、新辅助系统治疗、辅助放疗和边缘阳性有关(均为 p &;lt;.05)。每家医院的中期死亡率中位数为 4.5%(IQR 2.6-6.5)。四分位数最高的医院采用新辅助系统疗法、新辅助放疗和辅助放疗的几率较低(均为 p &;lt;.05)。神经网络提名图在预测个体化中期死亡风险方面具有很高的准确性(准确率:0.9499;AUC-ROC:0.7531)。结论 近 10%的癌症胰腺切除术患者在 6 个月内死亡,其中一半发生在中期。这些数据对改善讨论根治性胰腺切除术时的共同决策具有现实意义。
Assessment of Intermediate-Term Mortality Following Pancreatectomy for Cancer
Background Pancreatic cancer remains highly lethal and resection represents the only chance for cure. Although patients are counseled regarding short-term (0-3 months) mortality, little is known about mortality 3-6 months (intermediate-term) following surgery. We assessed predictors of intermediate-term mortality, evaluated hospital-level variation, and developed a nomogram to predict intermediate-term mortality risk. Methods Patients undergoing pancreatic cancer resection were identified from the National Cancer Database (2010-2020). Multivariable logistic regression identified predictors of intermediate-term mortality and assessed differences between short-term and intermediate-term mortality. Multinomial regression grouped by intermediate-term mortality quartiles evaluated hospital-level variation. A neural network model was constructed to predict intermediate-term mortality risk. All statistical tests were 2-sided. Results Of 45,297 patients, 3,974 (8.9%) died within 6-months of surgery of which 2,216 (5.1%) were intermediate-term. Intermediate-term mortality was associated with increasing T-category, positive nodes, lack of systemic therapy, and positive margins (all p < .05) compared with survival beyond 6-months. Compared with short-term, intermediate-term mortality was associated with treatment at high-volume hospitals, positive nodes, neoadjuvant systemic therapy, adjuvant radiotherapy, and positive margins (all p < .05). Median intermediate-term mortality rate per hospital was 4.5% (IQR 2.6-6.5). Highest quartile hospitals had decreased odds of treatment with neoadjuvant systemic therapy, neoadjuvant radiotherapy, and adjuvant radiotherapy (all p < .05). The neural network nomogram was highly accurate (Accuracy: 0.9499; AUC-ROC of 0.7531) in predicting individualized intermediate-term mortality risk. Conclusion Nearly 10% of patients undergoing pancreatectomy for cancer died within 6-months of which half occurred in the intermediate-term. These data have real-world implications to improve shared decision-making when discussing curative-intent pancreatectomy.